Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
January 08, 2024 16:05 ET
|
Atea Pharmaceuticals, Inc.
A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650...
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
Fundable for Life, Inc. Partners with The Latino Franchise Association to Provide its Clients TV and Digital Print Media Along with Funding Options
December 21, 2023 08:00 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
Fundable for Life, Inc. Partners with Boston BioLife to Provide its Members TV and Digital Print Media Along with Funding Options
December 18, 2023 08:00 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
Fundable for Life, Inc. Partners with FMS Franchise to Provide its Clients TV and Digital Print Media Along with Funding Options
December 13, 2023 08:00 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
Fundable for Life, Inc. Partners with Top Doctor Magazine to Provide its Members TV and Print Media Along with Funding Options
December 11, 2023 13:05 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
Re:Dish Secures Spot on Inc.'s 2023 Best in Business List By Eliminating Nearly 2 Million Single-Use Packaging Items in First Full Year of Operation
December 05, 2023 10:48 ET
|
Re:Dish Co.
Re:Dish Secures Spot on Inc.'s 2023 Best in Business List By Eliminating Nearly 2 Million Single-Use Packaging Items in First Full Year of Operation
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
November 13, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study Plasma Pharmacokinetic (PK) Profiles of Bemnifosbuvir and Ruzasvir Were...
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023 16:05 ET
|
Atea Pharmaceuticals, Inc.
Patient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24 Phase 2 bemnifosbuvir and ruzasvir combination trial for...
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
November 08, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...